Catalent Inc

NYSE:CTLTUnited States

Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. It also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.

Contact Information

Headquarters

14 Schoolhouse RdSOMERSET, NJ, United States 08873-1213

Phone

732-537-6200

Fax

732-537-6480

Executives

Executive Chairman of the Board

John Greisch

President, Chief Executive Officer, Director

Alessandro Maselli

President, Division Head for BioProduct Delivery and Chief of Staff

Ricky Hopson

Chief Financial Officer, Senior Vice President

Matti Masanovich

Group President - Pharma and Consumer Health

Aristippos Gennadios